# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://patentcenter.uspto.gov/applications/17316585/ifw/docs
- SEC Filing
The treatment response results of 22% following 8 weeks of twice weekly HyBryte therapy reinforces and confirms the results of ...
Includes thermostabilized Ebola vaccines MarVax and SuVax Includes nanoemulsion adjuvant compatible with lyophilization